PDF(Pubmed)
Abstract：
UNASSIGNED: The coronavirus disease 2019 (COVID-19) pandemic has severely affected healthcare systems around the world. This study aimed to investigate the perceptions of cardiologists regarding how the COVID-19 pandemic has affected the clinical practice patterns for acute coronary syndrome (ACS).
UNASSIGNED: A multicenter clinician survey was sent to 300 cardiologists working in 22 provinces in China. The survey collected demographic information and inquired about their perceptions of how the COVID-19 pandemic has affected ACS clinical practice patterns.
UNASSIGNED: The survey was completed by 211 (70.3%) cardiologists, 82.5% of whom were employed in tertiary hospitals, and 52.1% reported more than 10 years of clinical cardiology practice. Most respondents observed a reduction in ACS inpatients and outpatients in their hospitals during the pandemic. Only 29.9% of the respondents had access to a dedicated catheter room for the treatment of COVID-19-positive ACS patients. Most respondents stated that the COVID-19 pandemic had varying degrees of effect on the treatment of acute ST-segment elevation myocardial infarction (STEMI), acute non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina. Compared with the assumed non-pandemic period, in the designed clinical questions, the selection of coronary interventional therapy for STEMI, NSTEMI, and unstable angina during the COVID-19 pandemic was significantly decreased (all p < 0.05), and the selection of pharmacotherapy was increased (all p < 0.05). The selection of fibrinolytic therapy for STEMI during the pandemic was higher than in the assumed non-pandemic period (p < 0.05).
UNASSIGNED: The COVID-19 pandemic has profoundly affected ACS clinical practice patterns. The use of invasive therapies significantly decreased during the pandemic period, whereas pharmacotherapy was more often prescribed by the cardiologists.
UNASSIGNED: A multicenter clinician survey was sent to 300 cardiologists working in 22 provinces in China. The survey collected demographic information and inquired about their perceptions of how the COVID-19 pandemic has affected ACS clinical practice patterns.
UNASSIGNED: The survey was completed by 211 (70.3%) cardiologists, 82.5% of whom were employed in tertiary hospitals, and 52.1% reported more than 10 years of clinical cardiology practice. Most respondents observed a reduction in ACS inpatients and outpatients in their hospitals during the pandemic. Only 29.9% of the respondents had access to a dedicated catheter room for the treatment of COVID-19-positive ACS patients. Most respondents stated that the COVID-19 pandemic had varying degrees of effect on the treatment of acute ST-segment elevation myocardial infarction (STEMI), acute non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina. Compared with the assumed non-pandemic period, in the designed clinical questions, the selection of coronary interventional therapy for STEMI, NSTEMI, and unstable angina during the COVID-19 pandemic was significantly decreased (all p < 0.05), and the selection of pharmacotherapy was increased (all p < 0.05). The selection of fibrinolytic therapy for STEMI during the pandemic was higher than in the assumed non-pandemic period (p < 0.05).
UNASSIGNED: The COVID-19 pandemic has profoundly affected ACS clinical practice patterns. The use of invasive therapies significantly decreased during the pandemic period, whereas pharmacotherapy was more often prescribed by the cardiologists.
摘要：
■2019年冠状病毒病（COVID-19）大流行严重影响了世界各地的医疗保健系统。这项研究旨在调查心脏病专家对COVID-19大流行如何影响急性冠状动脉综合征（ACS）的临床实践模式的看法。
■向中国22个省的300名心脏病专家发送了一项多中心临床医生调查。该调查收集了人口统计信息，并询问了他们对COVID-19大流行如何影响ACS临床实践模式的看法。
■这项调查由211名（70.3%）心脏病专家完成，其中82.5%受雇于三级医院，52.1％的人报告了超过10年的临床心脏病学实践。大多数受访者观察到，在大流行期间，其医院的ACS住院患者和门诊患者减少。只有29.9%的受访者可以使用专用导管室治疗COVID-19阳性ACS患者。大多数受访者表示，COVID-19大流行对急性ST段抬高型心肌梗死（STEMI）的治疗有不同程度的影响，急性非ST段抬高型心肌梗死(NSTEMI),和不稳定型心绞痛.与假定的非大流行期相比，在设计的临床问题中，STEMI冠状动脉介入治疗的选择，NSTEMI,COVID-19大流行期间的不稳定型心绞痛明显减少（均p<0.05），药物治疗的选择增加(均p<0.05)。大流行期间STEMI纤溶疗法的选择高于假定的非大流行期（p<0.05）。
■COVID-19大流行深刻影响了ACS的临床实践模式。在大流行期间，侵入性治疗的使用显着减少，而药物治疗更多是由心脏病专家开的。
■向中国22个省的300名心脏病专家发送了一项多中心临床医生调查。该调查收集了人口统计信息，并询问了他们对COVID-19大流行如何影响ACS临床实践模式的看法。
■这项调查由211名（70.3%）心脏病专家完成，其中82.5%受雇于三级医院，52.1％的人报告了超过10年的临床心脏病学实践。大多数受访者观察到，在大流行期间，其医院的ACS住院患者和门诊患者减少。只有29.9%的受访者可以使用专用导管室治疗COVID-19阳性ACS患者。大多数受访者表示，COVID-19大流行对急性ST段抬高型心肌梗死（STEMI）的治疗有不同程度的影响，急性非ST段抬高型心肌梗死(NSTEMI),和不稳定型心绞痛.与假定的非大流行期相比，在设计的临床问题中，STEMI冠状动脉介入治疗的选择，NSTEMI,COVID-19大流行期间的不稳定型心绞痛明显减少（均p<0.05），药物治疗的选择增加(均p<0.05)。大流行期间STEMI纤溶疗法的选择高于假定的非大流行期（p<0.05）。
■COVID-19大流行深刻影响了ACS的临床实践模式。在大流行期间，侵入性治疗的使用显着减少，而药物治疗更多是由心脏病专家开的。
